9
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61304 |
FGFR2-IN-1
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR2-IN-1是一种 FGFR 抑制剂,对 FGFR1、FGFR2和FGFR3具有抑制作用, IC50 分别为460、140和2200 nM。FGFR2-IN-1 可用于研究与 FGFR2 相关的癌症。 | |||
T60185 |
FGFR2-IN-3
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR2-IN-3 是一种具有口服活性的选择性 FGFR2抑制剂。 | |||
T5044 |
Futibatinib
TAS120,FGFR-IN-1 |
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Futibatinib (FGFR-IN-1) 是口服具有活力的、选择性强的、高生物利用度的、不可逆的 FGFR 抑制剂。它抑制突变型和野生型 FGFR2,且 IC50相似(wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM)。 | |||
T62653 |
FGFR-IN-2
|
||
FGFR-IN-2 (compound 1) 是一种有效的 FGFR 抑制剂,能够作用于 FGFR1 (IC50: 7.3 nM)、FGFR2 (IC50: 4.3 nM)、FGFR3 (IC50: 7.6 nM) 和 FGFR4 (IC50: 11 nM)。FGFR-IN-2 具有潜力进行癌症研究。 | |||
T39001 |
FGFR-IN-1
|
||
FGFR-IN-1 is a highly effective inhibitor targeting the Fibroblast Growth Factor Receptor (FGFR) group, comprising FGFR1, FGFR2, and FGFR3, with an impressive inhibitory concentration (IC 50) of less than 100 nM (US20130338134A1, example 219). | |||
T64107 |
FGFR3-IN-1
|
||
FGFR3-IN-1 (compound 1) 是一种成纤维细胞生长因子受体 (FGFR) 抑制剂,可抑制FGFR1 (IC50: 40 nM),FGFR2 (IC50: 5.1 nM) 和 FGFR3 (IC50: 12 nM)。FGFR3-IN-1 能够用于研究膀胱癌。 | |||
T77816 |
Deruxtecan analog 2
|
||
Deruxtecananalog 2(示例9 P3)是一种含活性分子-linker的Deruxtecan类似物,由Camptothecin(一种对多种癌症如结直肠癌、乳腺癌、肺癌和卵巢癌具有抗肿瘤活性的Topo I抑制剂)和linker组成,主要用于开发针对EGFR2的抗体药物偶联物(ADC)活性分子。 | |||
T69162 |
Ki23057
|
||
Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism betwee... | |||
T79257 | FGFR-IN-11 | FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR-IN-11(compound I-5)是一款具备口服活性的共价pan-FGFR抑制剂,对FGFR1至FGFR4的IC50值分别为9.9 nM、3.1 nM、16 nM和1.8 nM。该化合物能够在纳摩尔水平有效抑制多种肿瘤细胞的增殖,并在荷瘤小鼠模型中显著地抑制肿瘤生长。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2S0007 |
Ferulic acid sodium
阿魏酸钠,阿魏酸钠;3-甲氧基-4-羟基肉桂酸钠,Sodium ferulic,Ferulic acid sodium salt,Sodium ferulate |
FGFR; Reactive Oxygen Species; 5-HT Receptor; Endogenous Metabolite | Angiogenesis; GPCR/G Protein; Immunology/Inflammation; Metabolism; Neuroscience; NF-κB; Tyrosine Kinase/Adaptors |
Ferulic acid sodium (Sodium ferulic) 是新型的成纤维细胞生长因子受体 1 (FGFR1) 抑制剂。它对于FGFR1和FGFR2的IC50分别为 3.78 and 12.5 μM。 | |||
T2215 |
Ferulic Acid
Coniferic acid,Fumalic Acid,阿魏酸 |
FGFR; Endogenous Metabolite | Angiogenesis; Metabolism; Tyrosine Kinase/Adaptors |
Ferulic Acid (Coniferic acid) 是新型的成纤维细胞生长因子受体 1 (FGFR1)抑制剂, 在FGFR1和FGFR2的IC50分别为 3.78 和 12.5 μM。 |